J&J shrugs off deals with Aduro that were worth up to $1.2B. Setback forces shift to Novartis alliance now
Back in the spring of 2014, J&J inked the first of two licensing pacts for the year with Aduro, looking to benefit from the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
